Company intelligence / Profile preview

Olavide Neuron STX

Seville, Andalusia, Spain

Ownership: Private
Development stage: Other

Overview

Olavide Neuron STX is developing ONESTX-1, an oral steroid sulfatase (STS) inhibitor designed to stabilize neurosteroids and treat age-related neurodegenerative diseases. As of mid-2025, the company has secured funding to transition its lead program into Phase 1 clinical trials to demonstrate safety and efficacy in patients with Alzheimer's and other neurodegenerative conditions.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Universidad Pablo de OlavideBiomedal

Beyond the preview

Go deeper on Olavide Neuron STX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olavide Neuron STX.

Explore the full profile